We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+17.01%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$5.66B
AUM Growth
+$1B
Cap. Flow
+$784M
Cap. Flow %
13.85%
Top 10 Hldgs %
43.17%
Holding
164
New
34
Increased
29
Reduced
25
Closed
18

Top Buys

Rank Stock Value
1
INTC icon
Intel
INTC
+$47.7M
2
ARGX icon
argenx
ARGX
+$47.4M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$44.5M
4
IMA
ImageneBio Inc
IMA
+$44.2M
5
ACHL
Achilles Therapeutics
ACHL
+$37.3M

Top Sells

Rank Stock Value
1
GDS icon
GDS Holdings
GDS
+$89.7M
2
Z icon
Zillow
Z
+$66.8M
3
ONC
BeOne Medicines Ltd
ONC
+$49.7M
4
BABA icon
Alibaba
BABA
+$46.5M
5
QURE icon
uniQure
QURE
+$25.3M

Sector Composition

Rank Sector Weight
1 Healthcare 68.71%
2 Consumer Discretionary 8.71%
3 Technology 1.72%
4 Communication Services 0.79%
5 Real Estate 0.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRAX icon
51
Praxis Precision Medicines
PRAX
$8.11B
$24.6M 0.43%
50,000
– –
REPL icon
52
Replimune Group
REPL
$454M
$24.4M 0.43%
800,000
+100,000
+14% +$3.74M
VOR icon
53
Vor Biopharma
VOR
$1.06B
$23.7M 0.42%
+27,500
New +$23.3M
ADVM
54
DELISTED
Adverum Biotechnologies
ADVM
$23.7M 0.42%
240,000
-10,000
-4% -$1.2M
NEXI
55
DELISTED
NexImmune, Inc. Common Stock
NEXI
$22.9M 0.4%
+48,000
New +$26.1M
NG icon
56
NovaGold Resources
NG
$2.54B
$22.8M 0.4%
2,600,000
– –
FHTX icon
57
Foghorn Therapeutics
FHTX
$278M
$22.7M 0.4%
1,720,720
– –
SQZ
58
DELISTED
SQZ Biotechnologies Company
SQZ
$22M 0.39%
1,606,309
+1
+0% +$20
GOSS icon
59
Gossamer Bio
GOSS
$101M
$21.8M 0.39%
2,358,968
– –
ALBO
60
DELISTED
Albireo Pharma Inc
ALBO
$21.1M 0.37%
600,000
-100,000
-14% -$3.69M
TSHA icon
61
Taysha Gene Therapies
TSHA
$1.61B
$21.1M 0.37%
1,040,882
– –
HARP
62
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$20.9M 0.37%
100,000
+20,000
+25% +$4.01M
DRNA
63
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$20.5M 0.36%
+800,000
New +$20.4M
CRIS icon
64
Curis
CRIS
$9.71M
$20.4M 0.36%
4,512
– –
RNAC icon
65
Cartesian Therapeutics
RNAC
$218M
$20.4M 0.36%
150,000
– –
NTLA icon
66
Intellia Therapeutics
NTLA
$1.51B
$20.1M 0.35%
250,000
– –
CPNG icon
67
Coupang
CPNG
$27.2B
$19.7M 0.35%
+400,000
New +$18.5M
MRSN
68
DELISTED
Mersana Therapeutics
MRSN
$19.4M 0.34%
48,000
– –
APTX
69
DELISTED
Aptinyx Inc. Common Stock
APTX
$18.3M 0.32%
6,116,493
+3,614,458
+144% +$13M
BLU
70
DELISTED
BELLUS Health Inc.
BLU
$18.2M 0.32%
4,750,000
– –
IQ icon
71
iQIYI
IQ
$1.19B
$17M 0.3%
1,025,000
+175,000
+21% +$4.04M
KURA icon
72
Kura Oncology
KURA
$793M
$17M 0.3%
600,000
– –
RPTX
73
DELISTED
Repare Therapeutics
RPTX
$16.9M 0.3%
550,000
-20,000
-4% -$679K
TCRR
74
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$16.6M 0.29%
750,000
+250,000
+50% +$6.82M
TBIO
75
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$16.5M 0.29%
1,000,000
-200,000
-17% -$4.56M
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2021 Portfolio in Review

As of Q1 2021, Artal Group held 164 positions worth $5.66B, up 21% from $4.66B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Artal Group deployed $784M of net new capital in Q1 2021, opening 34 new positions and adding to 29 existing holdings. Its largest new stake was Intel: 800,000 shares worth $51.2M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 77% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was GDS Holdings, an estimated $89.7M trimmed.

  • Artal Group's largest Q1 2021 buy was Intel: 800,000 shares worth $51.2M.
  • Artal Group added most to argenx in Q1 2021, an estimated $47.4M increase.
  • Artal Group's biggest Q1 2021 reduction was GDS Holdings, cutting an estimated $89.7M.
  • Artal Group fully exited Alibaba in Q1 2021, selling an estimated $46.5M.
  • Artal Group's ten largest holdings make up 43% of its $5.66B portfolio in Q1 2021.
  • Artal Group opened 34 new positions and closed 18 in Q1 2021.
  • Artal Group's portfolio value rose 21% quarter-over-quarter to $5.66B.

Based on Artal Group's 13F filing for Q1 2021, filed 14 May 2021.